Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment‐naïve patients with chronic hepatitis B following entecavir therapy

Abstract

This study aimed to evaluate the clinical usefulness of the aminotransferase to platelet ratio index (APRI), fibrosis‐4 (FIB‐4), and modified FIB‐4 (mFIB‐4) indices in predicting hepatocellular carcinoma (HCC) in patients receiving entecavir (ETV) treatment.